Search company, investor...

Stage

Series B | Alive

Total Raised

$14.57M

Last Raised

$11.97M | 6 yrs ago

About Acousia Therapeutics

Acousia Therapeutics is a biotech company focused on the development of innovative treatments for hearing loss. The company's main offering is the development of novel compounds, specifically small molecules, that aim to enhance and preserve natural hearing in patients suffering from sensorineural hearing loss. These therapeutic compounds are designed to be used as standalone treatments or in conjunction with hearing aids and cochlear implants. It is based in Tubingen, Germany.

Headquarters Location

Sindelfinger Straße 3

Tubingen, 72070,

Germany

Loading...

Loading...

Acousia Therapeutics Patents

Acousia Therapeutics has filed 2 patents.

The 3 most popular patent topics include:

  • audiology
  • auditory system
  • ear
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/27/2018

6/15/2021

Ion channels, Auditory system, Ear, Prodrugs, Audiology

Grant

Application Date

2/27/2018

Grant Date

6/15/2021

Title

Related Topics

Ion channels, Auditory system, Ear, Prodrugs, Audiology

Status

Grant

Latest Acousia Therapeutics News

Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial

Oct 9, 2023

Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ACOU085 in patients with cisplatin-induced hearing loss. Cisplatin-based chemotherapy, a lifeline for countless cancer patients, often delivers an unwanted side effect: irreversible hearing loss, i.e. ototoxicity, which occurs in 60% or more of cancer survivors. This makes the prevention of cisplatin-induced ototoxicity a significant unmet medical need for patients with a large potential market for a new therapeutic regimen. In a recently concluded Phase 1b clinical trial, ACOU085 demonstrated excellent safety and tolerability as well as long local residence time of the proprietary, sustained-release formulation, which is essential for providing extended otoprotection in acute hearing loss conditions such as cisplatin-induced ototoxicity. The Phase 2a multicentric, randomized, placebo-controlled, split-body trial will evaluate the efficacy of ACOU085 for preventing cisplatin-induced ototoxicity in young male patients diagnosed with testicular cancer. The clinical study will assess several efficacy outcomes for ACOU085, including changes in high-frequency, pure-tone audiometry, speech comprehension in quiet and noisy environments, and otoacoustic emissions. The enrolment of the first patients is expected in late 2023. Tim Boelke, CEO and Chief Medical Officer of Acousia, said: “Cisplatin is a lifeline for cancer patients, yet the heartache of hearing loss it brings is devastating. We are thrilled by the swift regulatory approval of our ACOU085 trial, which validates our development approach and offers the promise of hearing protection as patients battle cancer.” About Acousia Therapeutics GmbH Acousia Therapeutics GmbH is a privately held, clinical-stage biotech company based in Tübingen, Germany. The company is dedicated to the identification of small molecules for the effective prevention and treatment of different hearing loss etiologies. Acousia is focused on the development of proprietary drug candidates, which are designed to affect the sensory outer hair cells (OHC) in the cochlea of the inner ear. For example, the unique dual mode of action of its small-molecule Kv7.4 agonists, the acute functional OHC enhancement, and the sustained OHC protection aim to both enhance and preserve a patient’s natural hearing. Acousia Therapeutics develops drugs for both local and systemic administration. Rückfragen & Kontakt:

Acousia Therapeutics Frequently Asked Questions (FAQ)

  • Where is Acousia Therapeutics's headquarters?

    Acousia Therapeutics's headquarters is located at Sindelfinger Straße 3, Tubingen.

  • What is Acousia Therapeutics's latest funding round?

    Acousia Therapeutics's latest funding round is Series B.

  • How much did Acousia Therapeutics raise?

    Acousia Therapeutics raised a total of $14.57M.

  • Who are the investors of Acousia Therapeutics?

    Investors of Acousia Therapeutics include KfW, Boehringer Ingelheim Venture Fund, LBBW Venture Capital, Bregua, Creathor Ventures and 3 more.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.